Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

REGN+INO GBM at SITC, AACR, ESMO, and ASCO

Our next question comes from Esther Rajavelu with UBS.

Esther Rajavelu

Hi. Thank you for taking my questions. Can you talk a little bit about the Libtayo combo strategy with agents other than the bispecifics? I mean you have a number of Phase 2 trials ongoing with oncolytic viruses. So, curious what your thought process is there, and if we should be expecting to see any of those data readouts in the near-term?

Israel Lowy - REGN Senior Vice President, Transitional Sciences and Oncology

we also have – looking at DNA vaccines where we did a study with Inovio and their DNA vaccine platform in GBM. So, these are all in the early stages, exploratory stages. We hope we will be able to present data at meetings like SITC, AACR as well as ESMO and ASCO. And all I can say there is kind of stay tuned. We are pushing them all forward. And we picked these. We also have studies that we are looking at in combination with cellular therapy companies like bluebird and [indiscernible], because we believe there is opportunities for not just bispecifics, there may be reasons to try cellular therapies. So, we have a very broad outlook. We have, as a central foundation in our whole approach, have always believed that combination therapy is essential, and we have a very broad approach to that.

Regeneron Pharmaceuticals, Inc.'s (REGN) Management Presents at Regeneron Oncology Investor Event, ESMO 2021 Conference (Transcript)
Sep. 20, 2021 1:47 PM

https://seekingalpha.com/article/4456194-regeneron-pharmaceuticals-inc-s-regn-management-presents-regeneron-oncology-investor-event

“we plan to present at a fourth quarter cancer conference, our results of OS24 but also median OS. And I don't want to take the punchline but we have been achieving better than standard of care in each of those characteristics and milestones. So we couldn't be any happier in the progress from this trial.
We also plan to bring out what our next steps might be around that time. So as I said, Regeneron has been a wonderful partner and we look forward to executing with them this trial and potentially additional ones to come.“ 9/21/21 JK @Oppehheimer

Inovio Pharmaceuticals, Inc. (INO) CEO Joseph Kim on Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit Conference (Transcript)
Sep. 21, 2021 4:23 PM
https://seekingalpha.com/amp/article/4456431-inovio-pharmaceuticals-inc-ino-ceo-joseph-kim-on-oppenheimer-fall-healthcare-life-sciences